Robert Kraft Sells 3,858 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) Director Robert Kraft sold 3,858 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the sale, the director owned 955 shares in the company, valued at $590,008.55. This represents a 80.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Medpace Price Performance

NASDAQ MEDP opened at $600.65 on Friday. The stock has a market capitalization of $16.77 billion, a PE ratio of 35.21, a P/E/G ratio of 2.68 and a beta of 1.15. The business has a 50 day simple moving average of $565.33 and a two-hundred day simple moving average of $494.55. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $677.90.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Hedge Funds Weigh In On Medpace

Several large investors have recently modified their holdings of MEDP. Corient Private Wealth LP raised its holdings in Medpace by 291.4% during the 2nd quarter. Corient Private Wealth LP now owns 6,314 shares of the company’s stock valued at $3,344,000 after buying an additional 4,701 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Medpace in the 2nd quarter worth about $5,460,000. California State Teachers Retirement System lifted its stake in Medpace by 53,619.6% in the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after purchasing an additional 13,963,607 shares during the last quarter. HB Wealth Management LLC lifted its stake in Medpace by 3.9% in the second quarter. HB Wealth Management LLC now owns 1,858 shares of the company’s stock worth $984,000 after purchasing an additional 69 shares during the last quarter. Finally, AlphaGrep UK Ltd purchased a new position in shares of Medpace during the second quarter valued at approximately $466,000. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the topic of a number of recent research reports. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. BMO Capital Markets lifted their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday, July 24th. Royal Bank Of Canada lifted their price objective on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a report on Thursday, July 23rd. Finally, Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, August 12th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.